Sangamo Therapeutics, Inc

Sangamo Therapeutics is a U.S.-based genomic medicine company focused on developing therapies and enabling technologies built around zinc finger biology, epigenetic regulation, and engineered AAV capsids. Its business combines internal research programs in neurological and genetic diseases with out-licensing and collaboration agreements with large biopharmaceutical partners.

−296,5 %

−310,8 %

−31,6 %

0.84

0.84

— Sangamo Therapeutics, Inc
%
Therapeutic programs20% Internal drug-development programs targeting serious neurological and genetic diseases.
Capsid delivery licensing45% Licenses for the STAC-BBB capsid platform used to deliver genomic medicines to the CNS.
Research collaborations25% Partner-funded research, development support, and related collaboration services.
Milestones and royalties10% Upfront fees, development/commercial milestones, and potential future royalties.

Sangamo sells primarily to large biopharmaceutical companies through collaboration and license agreements, while also...

  • Biopharmaceutical collaboratorsprimary

    Buy platform licenses, target rights, and research collaboration access to Sangamo's technologies.

  • Strategic licensing partnersprimary

    License STAC-BBB and related capsid technologies for CNS delivery applications.

  • Clinical development stakeholderssecondary

    Patients, investigators, and advocacy groups that support trial enrollment and program design.

  • Potential commercial partnersemerging

    May license or co-develop late-stage assets for commercialization and market access.

Sangamo is headquartered in the United States and conducts its research, development, and corporate activities...

  • •Headquartered in the United States
  • •Research and corporate functions are centered in U.S. operations
  • •Collaboration agreements are global in scope
  • •Partner exposure includes U.S. and multinational pharma companies
  • •Geography matters more for regulation and partnering than for sales mix

Sangamo's strategy is to monetize its technology platforms through partnerships while advancing selected internal...

01
Fabry disease regulatory readinessshort-term

A late-stage submission can create a path to commercialization and partner interest.

02
CNS delivery partneringshort-term

STAC-BBB licensing can generate upfront fees and future milestones while validating the platform.

03
Pipeline and platform expansionmedium-term

Broader neurology programs increase the number of shots on goal and partnering opportunities.

Sangamo faces substantial financing, clinical development, and regulatory risk because it is a pre-commercial...

critical

Going concern and financing dependence

The company needs substantial additional capital to fund R&D and operations.

Scope
All programs and corporate continuity
Materiality
high
high

Collaboration revenue concentration and volatility

Revenue is driven by upfront fees, milestones, and partner reimbursements that can end or fluctuate.

Scope
Genentech, Lilly, Pfizer, Astellas and other partners
Materiality
high
high

Clinical and regulatory execution

Approval depends on trial data, endpoint acceptance, and FDA review outcomes.

Scope
Fabry BLA and CNS programs
Materiality
high
high

Nasdaq Capital Market compliance

Delisting would reduce trading liquidity and could further constrain financing options.

Scope
Common stock listing
Materiality
high
medium

Macroeconomic and capital market conditions

Biotech financing is sensitive to market risk appetite, rates, and sector sentiment.

Scope
Equity, debt, royalty, and strategic financing
Materiality
medium
Revenue recognition for collaborations and licenses
Drives quarter-to-quarter revenue swings
Long-lived asset impairment
Can create non-cash charges in operating expenses
Going-concern assessment
Material disclosure for investors and lenders
Stock-based compensation
Impacts reported R&D and G&A expense

Metagenomi Therapeutics, Inc.

MGX · Biological Products, (No Diagnostic Substances)

Relay Therapeutics, Inc.

RLAY · Biological Products, (No Diagnostic Substances)

Tango Therapeutics, Inc.

TNGX · Pharmaceutical Preparations

Gain Therapeutics, Inc.

GANX · Pharmaceutical Preparations

MUSTANG BIO, INC.

MBIO · Pharmaceutical Preparations

Axsome Therapeutics, Inc.

AXSM · Pharmaceutical Preparations

: 29/04/2026